Heart monitoring using left ventricle impedance and ventricular electrocardiography in left ventricular assist device patients by unknown
Her et al. BioMedical Engineering OnLine  (2015) 14:25 
DOI 10.1186/s12938-015-0019-3RESEARCH Open AccessHeart monitoring using left ventricle impedance
and ventricular electrocardiography in left
ventricular assist device patients
Keun Her1, Chi Bum Ahn2, Sung Min Park3 and Seong Wook Choi2** Correspondence: swchoe@
kangwon.ac.kr
2Department of Mechanical and




Full list of author information is
available at the end of the articleAbstract
Background: Patients who develop critical arrhythmia during left ventricular assist
device (LVAD) perfusion have a low survival rate. For diagnosis of unexpected heart
abnormalities, new heart-monitoring methods are required for patients supported
by LVAD perfusion. Ventricular electrocardiography using electrodes implanted in
the ventricle to detect heart contractions is unsuitable if the heart is abnormal. Left
ventricular impedance (LVI) is useful for monitoring heart movement but does not
show abnormal action potential in the heart muscle.
Objectives: To detect detailed abnormal heart conditions, we obtained ventricular
electrocardiograms (v-ECGs) and LVI simultaneously in porcine models connected
to LVADs.
Methods: In the porcine models, electrodes were set on the heart apex and
ascending aorta for real-time measurements of v-ECGs and LVI. As the carrier
current frequency of the LVI was adjusted to 30 kHz, it was easily derived from the
original v-ECG signal by using a high-pass filter (cutoff: 10 kHz). In addition, v-ECGs
with a frequency band of 0.1 – 120 Hz were easily derived using a low-pass filter.
Simultaneous v-ECG and LVI data were compared to detect heart volume changes
during the Q-T period when the heart contracted. A new real-time algorithm for
comparison of v-ECGs and LVI determined whether the porcine heartbeats were
normal or abnormal. Several abnormal heartbeats were detected using the LVADs
operating in asynchronous mode, most of which were premature ventricle contractions
(PVCs). To evaluate the accuracy of the new method, the results obtained were
compared to normal ECG data and cardiac output measured simultaneously using
commercial devices.
Results: The new method provided more accurate detection of abnormal heart
movements. This method can be used for various heart diseases, even those in
which the cardiac output is heavily affected by LVAD operation.Introduction
Ventricular assist devices (VADs) were developed to improve survival in patients with
advanced heart failure [1-5]. The use of VADs improves survival rates, and is in this
respect second only to heart transplantation [4,5]. VADs are commonly used as a
bridge-to-transplant measure, but their use as destination therapy is increasing due to
improved reliability and patient survival [5]. As the number of left ventricular assist© 2015 Her et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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detected in patients using VADs [6-9]. Ziv et al. suggested that the arrhythmia in these
patients may be caused by the VADs [7]. Bedi et al. also reported lower survival rates
in VAD patients who experienced arrhythmia within several weeks after LVAD im-
plantation [8]. Refaat et al. showed that an implantable cardioverter-defibrillator
(ICD) can increase the survivability of LVAD patients by properly treating critical
arrhythmia [9]. However, the majority of commercial VADs do not include a heart-
diagnosis function [10].
While electrocardiograms (ECGs) are necessary for diagnosis of arrhythmia, the
additional leads and electrodes from the ECG device are uncomfortable for a patient
who is already connected to a VAD. In addition, the VAD may interfere with the
ECG, preventing accurate monitoring of the heart [11-13]. Some VADs circumvent
the noise and other complications by connecting electrodes to the heart or subcuta-
neous tissues [14,15]. However, such electrodes are closer to the heart and the direc-
tion of measurement is altered, resulting in ECG recordings that deviate from
standard measures, in both waveform and magnitude [14]. Ventricular electrocardio-
grams (v-ECGs) taken directly from the heart rarely show noticeable differences be-
tween normal and abnormal heart activities, even with the occurrence of severe
abnormalities, such as premature ventricle contraction (PVC) [15]. Such limitations
make it difficult to use v-ECGs for diagnosis of arrhythmia. The use of left ventricle
impedance (LVI) has previously been suggested as a means of monitoring the heart in
VAD patients [16]. LVI is measured by connecting electrodes to the cardiac apex and
the aorta, and allows monitoring of changes in left ventricular volume. However, it
cannot determine whether a change in ventricle volume is caused by natural heart
muscle contraction and relaxation or by an inflow change resulting from the LVAD.
In the case of a pulsatile LVAD, using LVI signals alone to monitor the heart is difficult
due to the severely irregular blood inflow changes.
It is possible to record v-ECGs simultaneously with LVI, which is expected to provide
valuable data for diagnosing arrhythmia. The increment of LVI during the R-T period
can be derived from the v-ECGs. In addition, the changes in LVI signals during systole
can be predicted under the assumption that the heart contraction and LVAD inlet pres-
sure are stable with no changes caused by abrupt conditions or physiological factors.
Therefore, discrepancies between the predicted impedance and the measured LVI can
be interpreted as changes in heart performance since the initial recording. Using this
comparison, we have successfully detected reduced heart performance coinciding with
a PVC on an ECG.
In this study, LVI and v-ECG data were collected using electrodes linked to the hearts
of three pigs connected to VADs. The predicted increases in LVI were calculated under
simple conditions when the decrease in ventricle blood volume occurred due to heart
co1ntraction during the R-T period and LVAD inflow. In addition, the R-T period and
LVAD inflow period were determined from v-ECGs and the LVAD controller. During
the experiment, multiple PVCs were observed using conventional ECGs. When the
PVCs occurred, the measured LVI changes during R-T periods were lower than the
predicted values. The results of this experiment confirm that the LVI decrements dur-
ing the R-T period coincided with abnormal heartbeats, which could not be observed
using v-ECGs or LVI alone.
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v-ECG and LVI measurement method
The electrodes were placed at the inlet and outlet of the VAD, in contact with the apex
and aortic tissue, as shown in Figure 1. The electrodes were made of stainless steel with
smooth surfaces to prevent thrombogenesis and tissue adhesion. Although separate ani-
mal experiments showed neither thrombogenesis nor tissue adhesion for over 45 days,
long-term clinical trials may be needed to improve the performance and safety of the
electrodes [16]. In this study, the electrode material had no impact on v-ECG or LVI
measurements, and no measurement-induced damage or deformation of the electrodes
occurred.
For v-ECGs, a reference electrode was placed on the aorta, while the measurement
electrode was placed on the apex. This method has a similar direction of measurement
to aVF in ECG measurements, but with different polarity and magnitude because the
implanted electrodes are closer to the heart than the external electrodes used inFigure 1 Placement of electrodes for measurement of v-ECGs and LVI in the LV (upper) and pulsatile
left ventricular assist device (lower).
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the gain was 1000, which are similar values to those of conventional ECGs. The ampli-
fied signal was saved in 16-bit resolution through an analog-to-digital converter (ADC)
with a sampling rate of 250 Hz. LVI was measured by running a high-frequency current
at 30 kHz at 0.1 mA through the electrodes placed on the apex and the aorta. LVI
values were highest at the end of ventricular contraction or influx into the VAD, and
lowest before heart contraction.
Figure 2 shows the algorithms for real-time analysis of v-ECGs and LVI measure-
ments from a LVAD to monitor changes in heart activity. The left side of the algorithm
shows the following sequence: (1) measure the v-ECG and LVI; (2) use the same algo-
rithm to measure R-wave and T-wave; then (3) derive the change in LVI in the R-T
period. The middle section shows the algorithm for calculating the change in imped-
ance using the onset times of R- and T-waves, cardiac output (CO), and the duration
and volume of influx into the LVAD. The right section shows the algorithm for sending
the LVAD blood influx time and volume data to the impedance calculating algorithm
[17]. Finally, abnormal pulses are distinguished by comparing the predicted impedance
to the LVI value in the R-T period.
Measured v-ECGs show a negative R-wave value due to the inward sodium current
of heart cells at depolarization prior to contraction. The T-wave has a positive value on
the v-ECGs before relaxation due to the calcium and potassium current at repolariza-
tion. As shown in Figure 2 (a), the Tompkin method, which is used to find the QRS-Figure 2 Algorithm for (left) detection of R-T impedance increases, (right) VAD operation conditions,
and (middle and bottom) comparison of R-T impedance and prediction. (a) the R-wave detection in v-ECG,
(b) the T-wave detection, (c) the calculation of LVI change during R-T period, (d) the prediction of volume
change from v-ECG and LVAD inflow, (e) the impedance prediction, (f) the result of low-pass filter and (g) the
comparison of the predicted value and the measured.
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T-wave is defined as the peak that occurs 50 – 450 ms after the R-wave and with a
positive value greater than the threshold. (Other hemodynamic parameters are mea-
sured and compared to assess the accuracy of R- and T-waves, such as CO values de-
termined using an ultrasonic flow meter and arterial blood pressure (ABP) using a
monitor. The difference in R-wave detection time between v-ECGs and CO values was
16 ± 25 ms, and the difference between v-ECG and ABP was 22 ± 31 ms.)
During the R-T period, the decrease in LV volume is determined by blood flow into
the LVAD and the aorta through the aortic valve. The LV volume decrease can be mea-
sured by the change in LVI during the R-T period. The average inflow of a LVAD can
be estimated using the LVAD’s operating conditions and the total blood outflow from
the LV can be measured by the thermodilution method. Changes in cardiac impedance
are also affected by heart outflow. The blood flow through the aortic valve can be ob-
tained by subtracting the total blood outflow of the LVAD from the change in cardiac
volume during the R-T period. In addition, the blood flow through the aortic valve can
be measured using an ultrasonic blood flow meter. However, measurement using a
blood flow meter is possible for only a few minutes because the ascending aorta is an
unsuitable location for an ultrasonic flow-meter probe due to the narrow thoracic cav-
ity and the complexity of the vessels. Outside the R-T period, when heart contraction
does not occur, LV inflow through the mitral valve can also affect the volume and im-
pedance of the LV and make analysis of LVI difficult because no appropriate method
for measurement of LV inflow is available. Therefore, changes in LVI outside the R-T
period were not considered in this study.
LVI values are obtained at R- and T-waves and then the differences between these
values are used to calculate the LVI changes, as shown in Figure 2 (c). To estimate
heart activity, it should be determined whether the differences between the two LVI
values were due to LVAD inflow or outflow through the aortic valve, ejected by heart
contraction. The contraction phase can be recognized by the R-T period on v-ECGs,
and the correlation between the resulting decrease in ventricular volume and increased
heart impedance is well known [16]. During the R-T period, the magnitude of the de-
crease in volume can be predicted from the measured LVI; this decrease in volume can
be separated into the amount of blood exiting the ventricle through the aortic valve
and that entering the LVAD, as shown in equation 1.
LV volume decreaseR‐TPeriod ¼
Z T‐wave
R‐wave
FlowAortic Valve tð Þ þ inflowVAD tð Þð Þ dt ð1Þ
Here, the average VAD inflow can be calculated from VAD operating conditions [19].
The total average flow can be measured by subtracting the inflow to the VAD from the
flow measured by thermodilution. The increase in equation 1 during the R-T period
can be described by equation 2, which is composed of total average flow and average
inflow values.
LV volume decreaseR‐TPeriod ¼
TotalFlow‐InflowVADð Þ
HR
þ InflowVAD tR‐Τð Þ ð2Þ
The total average blood flow or thermodilution cannot be measured continuously;however, if it is assumed to be maintained at a stable value, it can be used to predict
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the predicted values with a 0.15-s moving average filter, as shown in Figure 2 (f ), the
filtered values can be compared with measured LVI to find changes in total average
blood flow. In Figure 2 (g), when the LVI change measured during the R-T period fell
below 50% of the predicted value calculated after the end of a T-wave, the difference
was attributed to abnormal performance of the heart.In vivo analysis
Animal experiments using three pigs (Yorkshire) weighing 35 – 40 kg were performed
with the approval of the Institutional Review Board of Kangwon National University
and in compliance with the Ethics and Regulations for Animal Studies. The animals
were placed on the operating table in the supine position, and 10 mg/kg intramuscular
ketamine was injected to induce anesthesia. Anesthesia was maintained during the sur-
gical procedure and the sensor-signal-monitoring period by a constant supply of 1 – 2%
inhaled isoflurane through an endotracheal tube. The inlet cannula (28 Fr; Medtronic
Inc., Minneapolis, MN) was connected to the LV apex, and the outlet cannula (16 Fr;
Medtronic Inc.) was connected to the ascending aorta through a median sternotomy.
Mean ABP was 47.7 ± 11.0 mm Hg before LVAD perfusion and 48.7 ± 8.3 mm Hg
during LVAD perfusion, mean heart rate (HR) was 86.7 ± 14.4 beats/min before LVAD
perfusion and 92.3 ± 4.7 beats/min during LVAD perfusion, mean CO was 3.4 ±
0.4 L/min before LVAD perfusion and 1.9 ± 0.6 L/min during LVAD perfusion, and
mean LVAD outflow was maintained at 1.3 ± 0.3 L/min. In all experiments, the ani-
mals survived for 3 h after starting the LVAD operation and were then euthanized by
an overdose of anesthetic.
The inlet and outlet cannulas of the LVAD (LibraHeart I; LibraHeart Inc., Chuncheon,
Korea) were connected to the animal’s LV and aorta, respectively, and the other ends of
the cannulas were connected to the inlet and outlet ports of the pump for use as a pulsa-
tile LVAD [15,19]. The v-ECGs were measured using electrodes set on the surfaces of the
inlet and outlet cannulas; the electrodes were in contact with the heart muscle and aorta
wall when the cannulas were connected [15,16,19]. v-ECG measurement on the LV is
similar to a unipolar-lead ECG measurement, except that the electrode contacts the car-
diac muscle directly; the measurable range is limited, and the pattern of waveforms is very
simple. LibraHeart I has an amplifier for the v-ECG with an amplification rate of 250×,
analog output, and an analog-to-digital converter (ADC; 250/s, 16-bit). LibraHeart I used
the measured v-ECG to detect the R-wave using Tompkin’s algorithm and to maintain the
LVAD in counterpulsation mode with the heart. Through the analog output, the measured
v-ECG was transmitted to an external data acquisition device (NI USB-6259; National In-
struments, USA) that could save measured v-ECGs with other vital signs from a patient
monitor (BPM1200; Bionics Inc., Korea).
Three additional electrodes were attached to both forelegs and the left rear leg of the
animals to compare the v-ECG measurements with those of conventional ECGs
(BPM1200; Bionics Inc., Korea), and ABP was measured at the carotid artery. After
connecting the cannula, v-ECG data were measured by the amplifier of the LVAD. All
measured data were immediately sent to a data-acquisition device (PXI6224; National
Instruments Corp., Austin, TX) through the analog channel.
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The v-ECG in Figure 3 (a) was obtained from the in-vivo experiment. It showed distinct
R-waves and T-waves on the v-ECG whether the heart beat were normal or abnormal.
However, many abnormal heart beats could not be identified with only the v-ECG;
although these abnormal signals could be found by analyzing the conventional ECG signal
measured at the same time (Figure 4 (a)). The R-T period could be calculated with the
v-ECG by measuring the delay from the R-wave to the T-wave according to the algorithm
shown in Figure 2 (a) and (b). The R-T period is shown in Figure 3 (b) and the y-axis of
Figure 3 (b) shows the average blood flow during the R-T period. Outside of the R-T
period, the aortic valve was assumed to be closed and the blood flow ceased.
The LVI shown in Figure 3 (c), measured simultaneously with the v-ECG, did not show
distinct aspects during heart contraction since the volume of the ventricle decreases not
only by the heart muscle’s contraction but also by the suction of the LVAD. However, the
LVI differences at the R-wave and the T-wave can show ventricular volume changes dur-
ing heart contraction as shown in Figure 3 (d). The average inflow amount of the LVAD
and inflow period were obtained from the LVAD controller as shown in Figure 3 (e).
The predicted heart volume in Figure 3 (f ) can be calculated using the values of the
average blood flow and LVAD inflow assuming those values remain in stable state. It
can be compared with the measured LVI changes and predicted heart volume as shown
in Figure 3 (g). When the measured LVI was less than half of the predicted value, the
heart beat was classified as abnormal because the volume change at the heart beat was
smaller than normal. Heart beats classified as abnormal were compared with a conven-
tional ECG, cardiac output (CO) and arterial blood pressure (ABP) in Figure 4. The
conventional ECG in Figure 4 (a) shows that most abnormal heart beats were PVC. CO
and ABP show that the blood flow through the aortic valve at PVC was significantly
smaller than for other normal beats. Table 1 verifies the reliability of the new compari-
son by showing distinct different values at normal heart beat and at PVC. VAD intake
caused a relatively small increase in LVI compared to the heart’s contraction. This
appears to be because the VAD intake of blood does not reduce the volume of the LV
by inducing blood inflow from the left atrium (LA).
Discussion
This study was performed to detect abnormal contraction of the heart by observing the im-
pedance of the LV. During these experiments, abnormal contractions were observed during
asynchronous perfusion with a pulsatile VAD. No previous study has indicated that the pul-
satile LVAD can induce abnormal heartbeat in asynchronous mode. However, such condi-
tions alter the load on the heart, and changes in cardiac load increase the risk of
arrhythmia. In cases in which arrhythmia is observed, an implantable cardioverter-
defibrillator (ICD) could be applied to the LVAD patient to treat advanced critical
arrhythmia. In addition to the change in load, sudden stretching of the cardiac muscle may
also stimulate the muscle and cause arrhythmias, such as PVC. Although these experiments
did not indicate a close correlation between stretching and PVC occurrence ratio, it is pos-
sible that these PVCs may be due to irregular volume changes caused by a pulsatile LVAD.
Previously, LVIs were measured using continuous flow VADs. In previous studies
using continuous flow VADs, the LVI and the amount of blood in the ventricles were
considered to be correlated. Unlike these previous experiments using continuous flow
Figure 3 (See legend on next page.)
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Figure 3 Signal processing for the detection of abnormal heart beats (a) the v-ECG recorded from the in-vivo
experiment, (b) the R-T period determined by the v-ECG in Figures 2 a, b, (c) the measured changes in
LVI, (d) the magnitude of change in LVI during the R-T period, as measured in Figure 2 c, (e) the period
during which blood flowed into the VAD, (f) the predicted increase in impedance during mean blood
flow and inflow from the heart when the R-T period and increase in volume appeared to predict high
impedance and (g) comparison of the predicted impedance in Figure 3 f and the actual LVI increase in
Figure 3 d.
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terns. As the measurement location and methods used in this study were identical to
those in previous studies, the same correlation was expected to be present using pulsa-
tile flow VADs. The precise correlation between LVI and ventricular volume may differ
between individual animals, because the amount of LV muscle and the irregular inflow
from the LA responsible for changes in LVI can differ according to the animal’s state.
Despite difficulties in analyzing original LVI, unexpected decreases in R-T impedance
changes could be compared with predicted values obtained using the new algorithm,
and the differences could facilitate identification of abnormal heart contraction. The
actual LVI was 18 ~ 24 ohms and the actual impedance changes were 2 – 3 ohms.
Abnormal LVI changes at PVC were 29.5% ± 12.4% smaller than normal. Abnormal
performance of the heart was defined as a decrease in performance to below 50%. Using
this as the definition of abnormal heartbeat, the P-value was below 0.05; therefore the ac-
curacy of this method appears adequate for detecting abnormal heartbeat. Distinguishing
the R-T period is a crucial part of LVI measurement. To determine whether the presence
or absence of PVC affects recognition of the R-T period, CO and the beginning and end
of a waveform were compared. The algorithms successfully recognized the R-T period re-
gardless of the occurrence of PVC. The hypothesis that the difference between theFigure 4 Simultaneous measurement of ECG, CO, and ABP.
Table 1 LVI increase during R-T period
LVI increment Comparison between lvi (r-t period)
& expectation (%)(Ohm, r-t period)
Normal #1:
0.277 ± 0.107 (n = 1041) 100.7 ± 11.2
#2:
0.395 ± 0.159 (n = 1467) 111.6 ± 13.8
#3:
0.424 ± 0.084 (n = 1693) 105.4 ± 11.5
Average
0.365 ± 0.117 (n = 4201) 105.9 ± 12.2
Abnormal (pvc) #1:
0.098 ± 0.051 (n = 110) 34.7 ± 17.8
#2:
0.127 ± 0.067 (n = 51) 33.7 ± 10.9
#3:
0.047 ± 0.028 (n = 36) 20.0 ± 8.5
Average
0.091 ± 0.049 (n = 197) 29.5 ± 12.4
Her et al. BioMedical Engineering OnLine  (2015) 14:25 Page 10 of 11predicted and actual LVI values is due to a change in cardiac performance requires the as-
sumption that the VAD maintains a constant output. Although actual VAD output can be
affected by a patient’s hemodynamic state, recently developed monitoring methods could
increase the accuracy of impedance prediction [17].
Although many arrhythmias were observed during the experiment, most were PVCs.
PVCs showed various temporal waveforms in ECGs depending on their origin in the
heart. PVCs have not been considered a critical abnormality, because they rapidly dis-
appear, are difficult to detect, and do not show distinct symptoms in ABP and HR. The
algorithm presented here shows that heart activity changes during PVCs and that these
short-term changes can be detected by this algorithm. However, additional experiments
are required to verify its ability to detect other types of arrhythmia.Conclusions
This study proposes a new approach to the analysis of heart activities by using ventricular
contractions, rather than the action potentials used in conventional ECGs. Comparison of
v-ECGs and impedances yielded relatively accurate values for LVI increase (R-T period) as
well as effective monitoring during events such as PVCs. This may aid in overcoming the
limitations of monitoring the heart and VAD by using solely flow rate and pressure, allow-
ing more detailed monitoring of the heart for functional diagnosis. In addition, by compar-
ing the experimental data with conventional flow, pressure, and ECG readings, the
method proposed here was shown to be the most reliable means of measuring the ven-
tricular volume, and therefore determining that of the heart. This method is expected to
be applicable as a biomonitoring technique in extracorporeal circulatory systems using
cannulas, such as extracorporeal membrane oxygenation (ECMO), as well as an effective
method for mointoring VAD patients.
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